Pasquale Martinelli

Pasquale Martinelli

Auto-generated profile, based on publicly available information

Pasquale Martinelli

Department of Neuroscience, Reproductive Sciences and Dentistry University of Naples Federico II Naples Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2016 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
HWHans Wolf
Hans Wolf
BAB. Arabin
B. Arabin
CLChristoph Lees
Christoph Lees
DOD. Oepkes
D. Oepkes
FPFederico Prefumo
Federico Prefumo
OGon behalf of the TRUFFLE group
on behalf of the TRUFFLE group
Objectives: To explore whether, in early fetal growth restriction (FGR), the longitudinal pattern of fetal heart rate (FHR) short‐term variation (STV) can be used to identify imminent fetal distress and whether abnormalities of FHR recordings are associated with 2‐year infant outcome.Methods: The original TRUFFLE study assessed whether, in early FGR, delivery based on ductus venosus (DV) Doppler pulsatility index (PI), in combination with safety‐net criteria of very low STV on cardiotocography (CTG) and/or recurrent FHR decelerations, could improve 2‐year infant survival without neurological impairment in comparison with delivery based on CTG monitoring only. This was a secondary analysis of women who delivered before 32 weeks and had consecutive STV data recorded > 3 days before delivery and known infant outcome at 2 years of age. Women who received corticosteroids within 3 days of delivery were excluded. Individual regression line algorithms of all STV values, except the last one before delivery, were calculated. Life tables and Cox regression analysis were used to calculate the daily risk for low STV or very low STV and/or FHR decelerations (below DV group safety‐net criteria) and to assess which parameters were associated with this risk. Furthermore, it was assessed whether STV pattern, last STV value or recurrent FHR decelerations were associated with 2‐year infant outcome.Results: One hundred and forty‐nine women from the original TRUFFLE study met the inclusion criteria. Using the individual STV regression lines, prediction of a last STV below the cut‐off used by the CTG monitoring group had sensitivity of 42% and specificity of 91%. For each day after study inclusion, the median risk for low STV (CTG group cut‐off) was 4% (interquartile range (IQR), 2–7%) and for very low STV and/or recurrent FHR decelerations (below DV group safety‐net criteria) was 5% (IQR, 4–7%). Measures of STV pattern, fetal Doppler (arterial or venous), birth‐weight multiples of the median and gestational age did not usefully improve daily risk prediction. There was no association of STV regression coefficients, a low last STV and/or recurrent FHR decelerations with short‐ or long‐term infant outcomes.Conclusion: The TRUFFLE study showed that a strategy of DV monitoring with safety‐net criteria of very low STV and/or recurrent FHR decelerations for delivery indication could increase 2‐year infant survival without neurological impairment. This post‐hoc analysis demonstrates that, in early FGR, the daily risk of abnormal CTG, as defined by the DV group safety‐net criteria, is 5%, and that prediction is not possible. This supports the rationale for CTG monitoring more often than daily in these high‐risk fetuses. Low STV and/or recurrent FHR decelerations were not associated with adverse infant outcome and it appears safe to delay intervention until such abnormalities occur, as long as DV‐PI is within normal range. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

17 March 2015 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
GSGabriele Saccone
Gabriele Saccone
LSLaura Sarno
Laura Sarno
ARAmanda Roman
Amanda Roman
VDVera Donadono
Vera Donadono
GMGiuseppe Maria Maruotti
Giuseppe Maria Maruotti
PMPasquale Martinelli
Pasquale Martinelli
To evaluate the efficacy of 5-methyl-tetrahydrofolate (5-MTHF) supplementation in prevention of recurrent preeclampsia. Retrospective cohort of women who received daily oral 5-MTHF 15 mg supplementation as prophylactic treatment since first trimester for recurrent preeclampsia were compared with women who did not. All asymptomatic singleton gestations with prior preeclampsia (in the previous pregnancy) were included. Women with chronic hypertension were excluded. The primary outcome was the incidence of preeclampsia. Three hundred and three singleton gestation met the inclusion criteria: 157 received 5-MTHF, while 146 did not (control group). Women who received 5-MTHF had a significantly lower incidence of recurrent overall preeclampsia (21.7% versus 39.7%; odds ratio (OR) 0.57, 95% confidence interval (CI) 0.25, 0.69), severe preeclampsia (3.2% versus 8.9%; OR 0.44, 95% CI 0.12-0.97) and early-onset preeclampsia (1.9% versus 7.5%; OR 0.34, 95% CI 0.07-0.87) compared to control. The intervention group delivered about 10 d after the control and had higher birth weight. This retrospective study showed that women with prior preeclampsia who received daily oral 5-MTHF 15 mg supplementation had a significantly lower incidence of overall preeclampsia, severe preeclampsia and early-onset preeclampsia. Randomized controlled trials are needed to confirm our findings.

1 March 2021 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
FCFrederic Chantraine
Frederic Chantraine
VSVedran Stefanovic
Vedran Stefanovic
TBThorsten Braun
Thorsten Braun
PCPavel Calda
Pavel Calda
PMPasquale Martinelli
Pasquale Martinelli
TGthe IS‐PAS group
the IS‐PAS group
Almost 10 years ago, clinicians at multiple locations all over Europe observed an increased number of antenatally undiagnosed cases of placenta accreta spectrum (PAS) resulting in significant morbidity and the occasional maternal death. Even with an improvement in antenatal imaging, the management of severe PAS remains challenging. One solution to improve understanding in rare but potentially lethal conditions is international collaboration. Consequently, a European working group was formed, which over the next few years grew into an international society, the IS‐PAS. The collective goals are to develop a large shared database of cases, generate high‐quality research into all aspects of PAS, and improve education of both healthcare professionals and patients. The first results of this collaboration are presented within this supplement.

17 July 2017 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
MFMarco Floridia
Marco Floridia
GMG. Masuelli
G. Masuelli
ETE. Tamburrini
E. Tamburrini
ICIrene Cetin
Irene Cetin
GLG. Liuzzi
G. Liuzzi
MRM. Ravizza
M. Ravizza
SUMMARY: Young pregnant women with HIV may be at significant risk of unplanned pregnancy, lower treatment coverage, and other adverse pregnancy outcomes. In a large cohort of pregnant women with HIV in Italy, among 2979 pregnancies followed in 2001–2016, 9·0% were in women <25 years, with a significant increase over time (2001–2005: 7·0%; 2006–2010: 9·1%; 2011–2016: 12·2%,P< 0·001). Younger women had a lower rate of planned pregnancy (23·2%vs.37·7%, odds ratio (OR) 0·50, 95% confidence interval (CI) 0·36–0·69), were more frequently diagnosed with HIV in pregnancy (46·5%vs.20·9%, OR 3·29, 95% CI 2·54–4·25), and, if already diagnosed with HIV before pregnancy, were less frequently on antiretroviral treatment at conception (<25 years: 56·3%; ⩾25 years: 69·0%, OR 0·58, 95% CI 0·41–0·81). During pregnancy, treatment coverage was almost universal in both age groups (98·5%vs.99·3%), with no differences in rate of HIV viral suppression at third trimester and adverse pregnancy outcomes. The data show that young women represent a growing proportion of pregnant women with HIV, and are significantly more likely to have unplanned pregnancy, undiagnosed HIV infection, and lower treatment coverage at conception. During pregnancy, antiretroviral treatment, HIV suppression, and pregnancy outcomes are similar compared with older women. Earlier intervention strategies may provide additional benefits in the quality of care for women with HIV.

1 January 2018 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
ARAmanda Roman
Amanda Roman
GSGabriele Saccone
Gabriele Saccone
SPSarah Pachtman
Sarah Pachtman
YCYury Cruz
Yury Cruz
BRBurt Rochelson
Burt Rochelson
VBVincenzo Berghella
Vincenzo Berghella

1 January 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
GSGabriele Saccone
Gabriele Saccone
GMGiuseppe M. Maruotti
Giuseppe M. Maruotti
VBVincenzo Berghella
Vincenzo Berghella
LSLaura Sarno
Laura Sarno
ACAngela Capone
Angela Capone
PMPasquale Martinelli
Pasquale Martinelli